{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"description":"An AE was defined as any untoward medical occurrence in a clinical study participant who received a pharmaceutical product, regardless of causality. An AE was , therefore, any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with AEs (including SAEs) are presented.","groups":[{"description":"Participants who received afamitresgene autoleucel 0.1x10\\^9 transduced cells","id":"OG000","title":"Afamitresgene Autoleucel, Group 1"},{"description":"Participants who received afamitresgene autoleucel 0.5-1.2x10\\^9 transduced cells","id":"OG001","title":"Afamitresgene Autoleucel, Group 2"},{"description":"Participants who received afamitresgene autoleucel 1.2-10x10\\^9 transduced cells","id":"OG002","title":"Afamitresgene Autoleucel, Group 3 + Expansion"},{"description":"Participants who received LDR in combination with lymphodepletion chemotherapy followed by the afamitresgene autoleucel infusion.","id":"OG003","title":"Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who received afamitresgene autoleucel or LDR/ afamitresgene autoleucel","reportingStatus":"POSTED","timeFrame":"From the start of lymphodepleting chemotherapy until end of interventional phase (up to 3.2 years).","title":"Adverse Events (AE) Including Serious Adverse Events (SAE)","type":"PRIMARY","unitOfMeasure":"Participants"}